A new nasal therapeutic HPV vaccine developed by Chiba University shows strong immune responses against cervical tumors in animal studies. The intranasal vaccine targets HPV16 and activates mucosal immunity, offering a potential non-invasive, fertility-preserving alternative to surgery, radiation, or chemotherapy if proven effective in humans.